Ardent Health, Inc. filings document the formal reporting record for a public healthcare provider operating acute care hospitals and related sites of care through subsidiaries. Form 8-K disclosures furnish quarterly operating results, including revenue, admissions measures, net patient service revenue, adjusted EBITDA, and related non-GAAP reconciliations.
The filing record also covers governance and capital-structure matters. Proxy materials describe annual-meeting proposals, director elections, executive compensation, equity awards, and pay-versus-performance data. Other 8-K filings report executive-separation and severance arrangements, a common stock repurchase authorization, and amendments to term loan and asset-based lending credit agreements involving subsidiary borrowers and guarantors.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine had 3,389 shares of common stock withheld for taxes upon vesting of restricted stock units on September 25, 2026, in accordance with Rule 16b-3. His direct holdings following the transaction were 325,794 shares.
Ardent Health, Inc. (ARDT) reported that Stephen C. Petrovich, EVP, GC and Secretary, had 788 shares withheld for taxes upon vesting of restricted stock units on September 25, 2026. The reported price was the $10.54 closing price per share. His direct common-stock holdings following the transaction were 773,919 shares. Separate indirect holdings are listed in the Stephen C. Petrovich GST-2016 Exempt Family Trust and Emilie K. Petrovich GST-2016 Exempt Family Trust; Petrovich disclaims beneficial ownership except to the extent of any pecuniary interests.
Ardent Health, Inc.'s SVP & Chief Accounting Officer, David Raynor Byers, had 524 common shares withheld for payment of taxes upon vesting of restricted stock units on September 25, 2026, in accordance with Rule 16b-3. The reported price was $10.54 per share, equal to the issuer's closing price that day. Byers directly held 129,921 shares after the transaction.
Ardent Health, Inc. (ARDT) filed an update to revise non-GAAP financial measures in its 2025 Form 10-K, removing $97.7 million of aggregate adjustments from Adjusted EBITDA and Adjusted EBITDAR related to a third-quarter 2025 accounts receivable collectability estimate and a New Mexico professional liability accrual.
After these changes, 2025 Adjusted EBITDA decreases from $545.0 million to $447.3 million, and 2025 Adjusted EBITDAR decreases from $709.3 million to $611.6 million. Ardent states these revisions follow discussions with the SEC’s Division of Corporation Finance and that its GAAP consolidated financial statements, financial condition, results of operations and cash flows remain unchanged.
The company confirms there are no revisions to 2023 or 2024 Adjusted EBITDA or Adjusted EBITDAR and no impact on 2026 financial results. The filing also restates definitions and reconciliations of Adjusted EBITDA and Adjusted EBITDAR, highlighting material addbacks such as interest, depreciation and amortization, restructuring costs, Epic implementation expenses, cybersecurity incident effects and rent expense payable to REITs.
Ardent Health, Inc. (ARDT) is the issuer for a planned resale of its common stock under Rule 144 by Martin Bonick, identified as a former officer and director. The notice covers 35,930 shares of common stock to be sold through Fidelity Brokerage Services LLC, with a stated aggregate market value of $398,030.92 and listing on the NYSE. The shares to be sold relate to restricted stock vesting on 06/02/2026, received from the issuer as compensation.
The filing also lists sales by Martin Bonick during the past three months: three transactions of 35,930 shares of Ardent Health common stock on 08/18/2026, 08/20/2026, and 08/25/2026, with reported aggregate sale prices of $393,481.70, $377,363.99, and $401,355.23, respectively. Fidelity Brokerage Services LLC signs the notice as attorney-in-fact for Martin Bonick.
Ardent Health, Inc. (ARDT) is the issuer for which former officer and director Martin Bonick has filed a notice of proposed sales of common stock under Rule 144. The shares are held in an account at Fidelity Brokerage Services LLC and are listed on the NYSE.
The notice covers up to 35,930 shares of common stock with an aggregate market value of $401,355.23 and a CUSIP-identifying number of 141045907, with a Rule 144 filing date of 08/25/2026. It also discloses that 7,088 shares and 28,842 shares of restricted stock are scheduled to vest on 04/01/2026 and 06/02/2026, respectively, as compensation from the issuer.
In the prior three months, Bonick sold 35,930 shares of ARDT common stock on 08/18/2026 for proceeds of $393,481.70 and another 35,930 shares on 08/20/2026 for proceeds of $377,363.99, as reported in this notice.
Ardent Health, Inc. (ARDT) is the issuer for a Rule 144 notice covering planned sales of common stock held for the account of former officer and director Martin Bonick. The filing lists up to 35,930 shares of common stock, with an aggregate market value of $377,363.99, proposed for sale on 08/20/2026 through Fidelity Brokerage Services LLC on the NYSE. It also notes that the shares to be sold include restricted stock vesting events of 8,994 shares on 03/31/2026 and 26,936 shares on 04/01/2026, received from the issuer as compensation, and discloses a prior sale of 35,930 shares on 08/18/2026 for $393,481.70.
Ardent Health, Inc. (ARDT) is the issuer for a planned resale of common stock under Rule 144 by former officer and director Martin Bonick. The shares are held at Fidelity Brokerage Services LLC. The notice lists a proposed sale on the NYSE on 08/18/2026.
The securities to be sold relate to restricted stock vesting awards from the issuer, including 19,990 shares vesting on 03/31/2025 and 15,940 shares vesting on 03/31/2026, both described as compensation. Fidelity signed the notice as attorney-in-fact for Bonick.
Ardent Health, Inc. reported softer profitability for the quarter ended June 30, 2026. Total revenue was $1.62 billion, down modestly from $1.65 billion a year earlier, but net income attributable to Ardent declined to $16.9 million from $72.9 million, and diluted EPS fell to $0.12 from $0.52.
Results were pressured by a lower contribution from Medicaid supplemental payment programs in the quarter, higher professional fees, self‑insured liability costs and increased general and administrative expenses, including severance and CEO transition costs. For the first six months, revenue rose to $3.22 billion, yet net income attributable to Ardent decreased to $56.7 million. Operating cash flow strengthened to $136.5 million, cash and cash equivalents increased to $724.5 million, and total debt stayed around $1.10 billion, while interest rate swaps moved from a larger net liability to a smaller one, improving other comprehensive income. The company continues to derive most revenue from Texas, Oklahoma and New Mexico, with a payer mix led by Medicare and other managed care.
Ardent Health reported second quarter 2026 revenue of $1.62 billion, down 1.4% year-over-year, as net patient service revenue per adjusted admission fell 3.9% after a prior-year benefit from the New Mexico state directed payment program. Net income attributable to Ardent was $17 million or $0.12 per diluted share, compared with $73 million or $0.52, and Adjusted EBITDA declined to $115 million, a 32.3% decrease. Adjusted admissions grew 2.5% while total surgeries fell 2.9%.
Operating cash flow strengthened to $197 million, up 67% from $117 million, contributing to cash of $724 million, total debt of $1.1 billion, a net leverage ratio of 0.8x and lease-adjusted net leverage of 2.6x as of June 30, 2026. Available liquidity was $992 million, and the company repurchased 1.4 million shares for $13 million, with $34 million remaining under its authorization.
For full-year 2026, Ardent reaffirmed total revenue guidance of $6.4–$6.7 billion and Adjusted EBITDA of $485–$535 million, while lowering net income attributable guidance to $110–$163 million and diluted EPS guidance to $0.78–$1.15. Targets for adjusted admissions growth of 1.5–2.5% and capital expenditures of $225–$265 million were maintained.